Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | mBCa: choosing the best treatment

Hannah Linden • 3 Jun 2019
ASCO 2019
Breast Cancer

Hannah Linden, MD, FACP, of the Seattle Cancer Care Alliance, Seattle, WA, discusses difficulties in choosing the best treatment option for metastatic breast cancer (mBCa). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Hannah Linden

0:58
Next steps in breast cancer molecular imaging
Hannah Linden • 3 Jun 2019
1:13
Molecular imaging in breast cancer
Hannah Linden • 2 Jun 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals